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The effect of eligibility 
for antiretroviral therapy on body 
mass index and blood pressure 
in KwaZulu‑Natal, South Africa
Aditi Kuber1,8, Anna Reuter1,7,8*, Pascal Geldsetzer2,7, Natsayi Chimbindi3, 
Mosa Moshabela3,4, Frank Tanser3,4,5,6, Till Bärnighausen3,7 & Sebastian Vollmer1
We use a regression discontinuity design to estimate the causal effect of antiretroviral therapy 
(ART) eligibility according to national treatment guidelines of South Africa on two risk factors for 
cardiovascular disease, body mass index (BMI) and blood pressure. We combine survey data collected 
in 2010 in KwaZulu‑Natal, South Africa, with clinical data on ART. We find that early ART eligibility 
significantly reduces systolic and diastolic blood pressure. We do not find any significant effects on 
BMI. The effect on blood pressure can be detected up to three years after becoming eligible for ART.
In 2019, 38 million people were estimated to be living with HIV, more than half of them living in Eastern and 
Southern  Africa1. In this region, about 70% of the people living with HIV (PLHIV) had access to antiretroviral 
treatment (ART) in  20191. ART increases life expectancy  drastically2–4, such that its expansion will trigger a 
change in the age composition of  PLHIV5. In 2007, adults aged 50 and above already constituted 14% of PLHIV 
in sub-Saharan  Africa6. If the present treatment coverage rates remain constant, the number of PLHIV aged 
50 + will triple over the coming  years7.
The expansion of ART and upsurge in life-expectancy of PLHIV might impact the burden of cardiovascular 
disease (CVD)8: As age is an important risk factor for CVD, the burden will increase with the aging of PLHIV. 
Additionally, observational studies indicate that PLHIV might be subject to a higher risk of CVD than their 
 counterparts9–11. Potential reasons are direct impacts of the virus on the body, unhealthy risk factors, comor-
bidities, or an association with the geographical variation of CVD  risks11. ART might mitigate the impact of 
HIV on CVD risks by viral suppression, but ART drugs might also increase CVD risks directly. Observational 
studies show an increased CVD risk for patients on ART compared to ART naïve PLHIV, especially for protease 
inhibitor-based  regimen9. However, the START randomized controlled trial suggests that the overall impact of 
early compared to deferred ART on CVD risk factors might be clinically negligible within the first  years12,13.
This study focuses on two intermediate risk factors of CVD; body mass index (BMI) and blood pressure. 
Similar to CVD risk, systematic literature reviews show that patients on ART have higher BMI and blood pres-
sure measurements, and higher odds of obesity and hypertension compared to ART naïve  patients14–16. The risk 
of developing hypertension seems to increase with duration of ART 17,18. Contrastingly, the START trial did not 
detect any significant impact of early compared to deferred ART on blood pressure or hypertension, but a small 
reduction in the use of blood pressure lowering  drugs13. Also, systematic literature reviews on sub-Saharan Africa 
do not find a significant association between ART and blood pressure or  hypertension19,20.
We add to this literature by investigating a natural experimental setting, in which we can estimate the causal 
effect of early ART eligibility on individual’s BMI, systolic blood pressure (SBP) and diastolic blood pressure 
(DBP). To this end, we employ a quasi-experimental technique which combines characteristics of observational 
studies and randomized controlled  trials21: Observational data from a large population-based sample allows us 
to analyze the ‘real-life’ effect of ART eligibility. While causal inference in an observational study usually requires 
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strong assumptions such as unconfoundedness, our quasi-experimental design allows us to replace this with 
weaker assumptions, such that we can plausibly identify the causal effect of early ART  eligibility22. Thus, our 
observational data gives us the advantage of a real-life context, while the quasi-experimental nature brings in an 
internal validity comparable to  RCTs21.
We exploit the fact that ART eligibility was determined by national guidelines during our observation period. 
Individuals with a CD4 cell count ≤ 200 cells/μl were eligible for ART, while individuals with a higher CD4 
count were asked to return for a reassessment after 6–12 months (with the exception of patients with TB, WHO 
stage IV, or pregnant women). In general, eligible patients might not be comparable to ineligible patients: For 
instance, the time from HIV infection to linkage-to-care is longer for  men23, and they initiate ART at lower CD4 
counts than  women24. However, patients presenting with similar CD4 counts can be assumed to be on average 
comparable to each other. Hence, individuals presenting with a CD4 cell count slightly below 200 cells/μl are 
plausibly similar to individuals with a CD4 count slightly above 200 cells/μl, except for the fact that the former 
received the possibility to initiate ART, while the later had to return after some time. Under certain assumptions, 
comparing the outcomes of these two groups gives us the causal effect of early versus deferred ART eligibility.
Methods
Data sources and procedures. We use data from a Demographic Information System run by the Africa 
Health Research Institute. The surveillance area is located in the Hlabisa sub-district of uMkhanyakude in Kwa-
Zulu-Natal25. The first round of data collection was conducted in 2000. Since 2003, data is collected every 6 
 months25. Individuals are included in the survey if they are considered as a member by one or more households 
within the surveillance area and have spent at least one night in this household within the past 12  months25.
During the surveillance period in 2010, a cross-sectional anthropometric survey was conducted in a random 
subsample of 30  areas26. All residents of the surveillance area > 15 years of age were  eligible27. WHO STEPS 
protocol was followed to measure height, weight and blood pressure. The survey addressed 4,608 individuals, of 
which 55% agreed to blood pressure and 45% to height and weight  measurement26.
We received data on ART eligibility from a linked clinic-based database. The database tracks laboratory data 
and clinic visits of HIV-positive individuals who accessed services at one of the 17 public health clinics within 
the surveillance area since  200728. Data on ART and CD4 counts prior to 2007 was collected retrospectively. CD4 
counts were measured at each clinic  visit28.
From 2004 to August 2011, adults with a CD4 count of ≤ 200 cells/μl or WHO stage IV HIV (pregnant 
women: WHO stage III) were eligible for ART, following national and WHO  guidelines29. Pregnant women and 
patients with tuberculosis were eligible with a CD4 count of ≤ 350 cells/μl since April  201029. Ineligible patients 
were asked to return to the clinic within six months if their CD4 count was ≤ 500 cells/μl, else within one  year28. 
Less than half of the patients which were ineligible returned within a year after the first clinic  visit30. Subsequent 
guidelines increased and finally abolished the threshold, but are not covered by our data.
Only individuals 15 years or older and with a non-missing value for at least one of the pairs height/weight, 
second/third SBP, or second/third DBP were considered. Patients who had been on ART treatment previously 
were excluded. As there was a substantial loss in care of patients not yet  eligible30, we only consider an individual’s 
earliest CD4 cell count. Also, only clinical data recorded between January 2007 (the first date of the database 
tracking) and the date of the anthropometric data collection were considered. Duplicates were dropped. The 
final sample consisted of 1132 patients. Data-driven optimal bandwidths as described in the statistical analysis 
reduced this number to 241 for the BMI analyses and 165 for the blood pressure analyses.
Ethical approval. The data is secondary to the authors. Primary data collection was approved by the Univer-
sity of KwaZulu-Natal’s Ethics Committee and administered by the Africa Health Research Institute. Informed 
consent was obtained from all study participants. All methods were carried out in accordance with relevant 
guidelines and regulations. Access to the anonymized data was granted by the Africa Health Research Institute 
for the purpose of this study.
Outcomes and covariates. We analyze the data for three outcomes, BMI, SBP, and DBP. We use data on 
weight and height collected in the anthropometric survey to calculate BMI scores by dividing weight (in kilo-
gram) by squared height (in meters). Due to missing observations for either of the two variables, BMI scores 
could be obtained for 943 individuals (83%) only. For SBP and DBP, the average of the second and third meas-
urement is calculated, as advised by the STEPS protocol. The average SBP and DBP could be calculated for 1,106 
individuals (98%).
Eligibility is defined as having a first CD4 cell count of ≤ 200 cells/μl, following the national treatment guide-
lines at that  time29. Deviation from this eligibility threshold was calculated as the difference between the first 
CD4 cell count and the threshold. Initiation of ART was defined as uptake of ART within 6 months after the first 
CD4 count test and before the survey date.
We use information on education years, age, squared age, sex, and years since the first CD4 test for balance 
checks and as controls in some of the regressions. Data on education was captured during another survey round 
in the same year.
Statistical analysis. We employ a regression discontinuity design to examine the effect of ART eligibility 
on BMI and blood pressure. At the time of the anthropometric survey, national guidelines created a threshold 
which divided patients based on their CD4 count into ART eligible and ineligible individuals. Under certain 
assumptions, this threshold is arbitrary to patients with a CD4 count very close to the threshold. For example, 
patients presenting with a CD4 count of 201 cells/μl and patients presenting with a CD4 count of 199 cells/
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μl are assumed to be on average very similar with respect to their clinical condition and sociodemographic 
background. It is assumed that the only difference between the two groups is that to the latter, ART was offered, 
while the former was advised to return after six months. Thus, any difference we see in BMI and blood pressure 
across the two groups is plausibly attributable to the offer of ART 31. The random noise in CD4 count measure-
ment further supports this assumption of a quasi-random assignment of eligibility in a small bandwidth around 
the  threshold31. However, in the absence of ART, the CD4 counts of PLHIV will decrease over time, bringing 
formerly non-eligible patients to the lower side of the threshold. Thus, any estimated difference will reflect the 
effect of early versus deferred ART eligibility.
The identification strategy hinges on the assumption that the groups just below and just above the threshold 
do not differ systematically except for their eligibility status. We employ two falsification tests by running a den-
sity check around the threshold following the procedure by Cattaneo et al.32 and a balance check using t-tests.
Similarly, the choice of the bandwidth around the threshold is crucial. Within a very small bandwidth, e.g., 
comparing individuals with a CD4 count + /− 1 CD4 cells/μl around the threshold, the individuals are convinc-
ingly similar, and the assumptions more likely to hold. At the same time, very small bandwidths contain only few 
observations, such that the power to detect any meaningful effects might be too small. To identify the optimal 
bandwidth around the threshold, we use a data-driven procedure minimizing the mean squared error (provided 
by the user-written Stata package rdrobust)33. For BMI, the optimal bandwidth is estimated at + /− 64 CD4 cells/
μl around the threshold, reducing the estimation sample to 241 individuals. For SBP and DBP, the optimal band-
width is estimated at + /− 40 CD4 cells/μl, reducing the estimation sample to 165 individuals.
As eligibility did not predict treatment uptake perfectly, we apply a reduced-form estimate to obtain the 
intention-to-treat effect at the threshold. We employ a linear functional form of the deviation of the CD4 count 
from the threshold to allow for a linear trend in our outcomes as the CD4 count increases. More specifically, our 
main estimation reads as follows:
Here, yi denotes the individual’s BMI, SBP or DBP at the time of the visit in 2010, Ei denotes eligibility (i.e., 
whether the CD4 count was below the threshold) and Di is the deviation from the threshold. β1 estimates the 
effect of early versus deferred ART eligibility.
In addition to the main specification, we analyze the robustness of the results to the inclusion of control 
variables using education, age, age squared, sex, and years since the CD4 test. We test for robustness to different 
bandwidths and to more flexible forms by employing higher-order polynomials. Finally, we analyze heterogene-
ous treatment effects by sex and over time using the following specification:
Here, Xki  denotes binary variables for each year since the CD4 test, respectively for sex. Thus, βk1 estimate 
the heterogeneous treatment effect by year since the CD4 test, respectively by sex. To obtain the total treatment 
effect for each distinct group, we test the linear combination of β1 and βk1 for joint significance using the lincom 
command. All other variables are defined as above. For all regression specifications, heteroskedasticity-robust 
standard errors are computed. All analyses are conducted with Stata 15.1 SE.
Results
Descriptive statistics. Balance checks for a bandwidth of + /− 50 CD4 cells/μl are depicted in Table 1. By 
design, ineligible and eligible participants differ according to their CD4 count. The two groups are statistically 
indistinguishable regarding all other covariates except for the years since the earliest CD4 test. On average, the 
CD4 test of eligible patients occurred three months earlier than the test of non-eligible patients. BMI, SBP and 
DBP do not differ between both groups in the simple means comparison.
Figure 1 depicts the estimated density of CD4 counts around the threshold. Using the test developed by Cat-
taneo et al. 32, we cannot reject the null hypothesis of a joint distribution.
The distribution of eligibility and treatment uptake over years and by sex are depicted in Fig. 2. The share 
of patients with a first CD4 cell count ≤ 200 cells/μl was especially high in 2008. Only a fraction of the patients 
(1)yi = β0 + β1Ei + β2Di + β3Ei · Di + ǫi











Table 1.  Balance checks for the ± 50 CD4 cells/μl bandwidth.
Not eligible Eligible
N Mean SD N Mean SD p-value
Female 98 0.83 0.38 123 0.85 0.36 0.7055
Age 98 38.14 11.88 123 36.92 10.72 0.4223
Education years 92 7.54 4.27 116 8.07 3.98 0.3611
Years since earliest CD4 test 98 2.40 1.01 123 2.66 0.95 0.0502
CD4 count at earliest CD4 test 98 228.95 12.97 123 174.92 14.68 0.0000
BMI 83 25.38 5.65 104 24.46 5.32 0.2525
SBP 98 117.62 18.54 118 117.13 15.88 0.8341
DBP 98 80.62 12.76 118 79.17 11.69 0.3844
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tested in 2010 already started ART by the time of the household visit in the same year. On average, men were 
more likely than women to become eligible at the first test.
Figure 3 depicts the distribution of treatment initiation, BMI, SBP and DBP over CD4 counts around the 
threshold. There is a clear jump in treatment probability at the threshold. Moreover, the polynomial fits suggest 
a reduction in SBP and DBP at the threshold.
Main results. Table 2 depicts the main estimates from Eq. (1) and the estimates using controls. We find no 
significant effect of ART eligibility on BMI in any of the specifications. However, there is a significantly negative 
effect of early ART eligibility on SBP and DBP (p < 0.05). On average, eligible patients have a 15.5 mmHg lower 
SBP and a 11.1 mmHg lower DBP compared to ineligible patients in the bandwidth around the threshold. This 
result is robust to the inclusion of socio-demographic controls.
Robustness checks. We assess the robustness of the results by employing different bandwidths and includ-
ing a quadratic function for the deviation from the threshold. We choose one smaller bandwidth of ± 25, approx-
imately halving the distance to the threshold, one larger bandwidth of ± 75, increasing the distance to the thresh-
old by the same span, and the largest possible symmetric bandwidth of ± 200. The coefficient estimates and 95% 
confidence intervals are depicted in Fig. 4. As before, there are no significant impacts of early ART eligibility 
on BMI compared to deferred eligibility. In the linear specification, the coefficient estimates for SBP and DBP 
in the smaller bandwidth are similar to the estimates in the optimal bandwidth, but not significantly different 
from zero due to the wider confidence interval. For both, SBP and DBP, the coefficient estimates move towards 
zero in the two wider bandwidths. In the quadratic specification, the coefficient estimate is significant at a 10% 
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Figure 1.  Estimated density of first CD4 counts with 95% confidence interval. The threshold lies at 200 CD4 
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Figure 2.  Share of individuals becoming eligible and starting treatment by year and sex.
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:14718  | https://doi.org/10.1038/s41598-021-94057-z
www.nature.com/scientificreports/
Heterogeneity by sex and year. Next, we test for heterogeneity by sex. As depicted in Table 3, there are 
significantly negative effects of ART eligibility on SBP and DBP for women, but not for men. However, the effects 
on the two groups are not statistically different from each other. There are only few observations for men (80% 
of the individuals within a ± 50 bandwidth are female), such that an effect different from zero or from the effect 
on women might not be detectable.
Finally, we investigate whether there are heterogeneous effects over time. As depicted in Fig. 5, there is a sig-
nificant negative effect of early ART eligibility on SBP and DBP in the second and third year, and for DBP also in 
the first year. The insignificant effect in the fourth year might be caused by several reasons: On the one hand, the 
treatment effect might diminish or change over time. On the other hand, due to the nature of HIV/AIDS, patients 
in the initially ineligible group will progress to ART eligibility over time, as their CD4 counts decline, thus 
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Figure 3.  Mean treatment initiation, BMI, SBP and DBP by CD4 cell count bins with 95% confidence intervals. 
The approximation is a second-order polynomial function differing on both sides of the threshold.
Table 2.  Estimates for linear specifications with and without controls. The controls are years of education, 
age, age squared, sex, and years since the CD4 test. Eligible* deviation refers to the interaction of the eligibility 
indicator and the deviation variable. The bandwidths are determined by a data-driven routine introduced in 
Calonico et al. 33. P-values are reported in parentheses, 95% confidence intervals in square brackets.
BMI SBP DBP
Eligible −0.956 −1.015 −15.50 −14.12 −11.14 −10.15
(0.5563) (0.5296) (0.0250) (0.0355) (0.0195) (0.0390)
[−4.150; 2.239] [−4.191; 2.161] [−29.03; −1.973] [−27.27; −0.975] [−20.47; −1.814] [−19.78; −0.521]
Eligible * 0.00555 −0.0151 0.297 0.0976 0.181 −0.0318
Deviation (0.8980) (0.7335) (0.2672) (0.7294) (0.3249) (0.8696)
[−0.0797; 0.0908] [−0.102; 0.0722] [−0.230; 0.824] [−0.459; 0.654] [−0.181; 0.543] [−0.414; 0.351]
Obs 241 224 165 155 165 155
Controls N Y N Y N Y
Bandwidth 64 64 40 40 40 40
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Figure 4.  Panel (A) depicts the coefficient estimates and 95% CI from Eq. (1) at different bandwidths. The 
data-driven optimal bandwidth for BMI, SBP and DBP is ± 64, ± 40, and ± 40 CD4 cells/μl, respectively. Panel (B) 
depicts the coefficient estimates and the 95% CIs from estimating Eq. (1) with addition of an quadratic function 
of the deviation. For comparability, the optimal bandwidth of the linear specification is used. The optimal 
quadratic bandwidths would be ± 100, ± 80 and ± 85, respectively. Results are robust to the employment of the 
optimal bandwidth for the quadratic specification.
Table 3.  Heterogeneity analysis by sex, using a linear specification. Coefficients are the sum of the base 
treatment effect and the respective group interaction effect. P-values are reported in parentheses, 95% 
confidence intervals in square brackets.
BMI SBP DBP
Male 0.113 −9.441 −8.579
(0.9573) (0.3604) (0.1831)
[−4.027;4.252] [−29.770;10.887] [−21.250;4.093]
Female −1.365 −16.029 −11.540
(0.3780) (0.0210) (0.0201)
[−4.408; 1.679] [−29.609; −2.450] [−21.243; −1.837]
Observations 241 165 165
Bandwidth 64 40 40

















Year 1 Year 2 Year 3 Year 4 Year 1 Year 2 Year 3 Year 4 Year 1 Year 2 Year 3 Year 4
BMI SBP DBP
Figure 5.  Heterogeneity analysis over time using a linear specification. Coefficient estimates and 95% 
confidence intervals are depicted. Year 1 depicts the estimates for the eligibility indicator, as year 1 was used 
as the base level in the regression. Years 2–4 depict the estimates of a linear combination of the base treatment 
effect plus the interaction effect with the respective year.
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Discussion
To our knowledge, our study is the first to identify the causal effects of early ART eligibility on BMI and blood 
pressure employing a regression discontinuity design. Our approach allows us to compare the BMI and blood 
pressure of individuals with similar characteristics except for ART eligibility. In contrast to approaches compar-
ing the change in BMI and blood pressure after ART initiation, or comparing BMI and blood pressure across 
ART naïve and ART individuals, this yields us the causal effect of early compared to deferred ART eligibility at 
the threshold of 200 CD4 cells/μl.
We do not find any significant effect of early ART eligibility on BMI. However, we find a significant negative 
effect of early ART eligibility on SBP (− 15.5 mmHg, CI [− 29.03; − 1.973]) and DBP (− 11.1 mmHg, CI [− 27.27; 
− 0.975]) in a bandwidth of + /− 40 CD4 cells/μl. As a reduction of SBP by 10 mmHg significantly reduces major 
CVD  events34, this impact is also clinically relevant. The effects are robust to controls and to using a quadratic 
function instead of a linear function for the running variable.
The null findings for BMI do not exclude any actual impact of ART on BMI. As BMI might incur substantial 
measurement error, our sample might not be sufficiently large to detect any changes. Alternatively, as weight 
gains might emerge over time, our observation period might be too small to identify significant differences to 
the control group, especially as previously ineligible patients are likely to become eligible sometime after the first 
CD4 test. Even so, our null results are in line with a meta-analysis for sub-Saharan Africa finding no association 
between BMI and ART across 36  studies20. Nevertheless, previous studies showed that especially stavudine and 
efavirenz, which were the most common treatment regimes in our sample at that time, can contribute to fat  loss35. 
At the same time, initial CD4 counts below 200 cells/μl were significantly associated with weight gains after treat-
ment  initiation36, which might result in counter-balancing effects on weight. It is possible that this changed over 
time, as newer ART regimes seem to be associated with more weight gain than older  regimes36. With the rising 
prevalence of overweight in southern  Africa37, any weight gains under newer ART regimes need to be carefully 
examined to differentiate between a return to a healthy weight and an increase in overweight and  obesity38.
ART eligibility might decrease blood pressure for several reasons. Firstly, antiretroviral drugs might decrease 
blood pressure. However, previous evidence suggests that some drug combinations rather increase blood 
 pressure15,39. Secondly, the information on ART eligibility and/or the transfer into treatment might alleviate 
patients’ distress regarding the lethal implications of HIV/AIDS. Quality of Life studies report an increase in 
the physical but also in the psychological and emotional dimension for patients after ART  initiation40. The 
improved well-being could transfer into a stress reduction and hence a decrease of the blood pressure level. 
Thirdly, the stress-blood pressure link could also work in the other direction: patients informed that they are 
(just) not eligible for treatment might be faced with a higher fear of dying from AIDS, which could raise their 
blood pressure. While a systematic literature review indicates a positive correlation between psychological stress 
and blood pressure, substantial variation in the definition and measurement of stress and blood pressure makes 
a conclusive assessment of this relationship  difficult41,42.
Empirically, there is mixed evidence on the link between ART and blood pressure. Globally, a positive cor-
relation is observed after one year of ART, with a progressively stronger correlation over duration of ART 15,17. 
There is evidence that an increase in BMI, the type of ART drugs, or both might mediate this  relationship15,39. 
For sub-Saharan Africa, no clear association of ART exposure with blood pressure or hypertension is  found19,20. 
However, the role of ART duration might matter: an observational study on the same population found a lower 
blood pressure for ART-exposed PLHIV compared to ART-naïve PLHIV, but a higher blood pressure for PLHIV 
which have been longer on ART 26. Thus, our results might be explained by a negative short-run effect of ART 
eligibility on blood pressure through stress reduction, but a positive long-run effect of ART on blood pressure 
through either the specific drugs, or weight increases observed in other  studies26,27.
Our study results should be treated with some caution. First of all, the identification in this regression dis-
continuity design is purely local, in the sense that it is estimated at the threshold. Hence, the estimated effect 
cannot be extrapolated to observations further away from the threshold without imposing further assumptions. 
As guidelines for ART eligibility were shifted to larger CD4 counts and finally lifted, our results explain impacts 
for patients presenting with comparatively low CD4 counts rather than for patients with comparatively high 
CD4 counts at the first test. Over time, the CD4 count at first presentation increased in the study  region43. The 
introduction of large testing programs over the past decade might have exacerbated this trend further, such that 
PLHIV are linked to care earlier and present with higher CD4 cell counts nowadays. After 2010, the threshold 
was increased at first to 350 cells/μl, then to 500 cells/μl, and finally lifted. Investigating the impact at these 
thresholds would be desirable to assess potential heterogeneous effects at higher CD4 cell count levels, but is 
not possible with our data, as the anthropometric measures were taken only in 2010. Secondly, the results might 
not be valid for different study settings. Finally, the share of non-responses in the anthropometric survey evokes 
the question of representativeness. In our quasi-experimental design, this additionally introduced problems of 
statistical power, which might be one reason why we cannot identify an impact on BMI.
Investigating the intermediate risk factors BMI, SBP and DBP, we do not find impacts of ART eligibility dur-
ing the ≤ 200 cells guideline in KwaZulu-Natal which would contribute to the risk of CVD. In contrast, using a 
rigorous regression discontinuity design we show that SBP and DBP in early-eligible patients with HIV decreased 
within the first years compared to patients with HIV with deferred eligibility. The effects of ART might differ 
under the new guidelines and across a longer time horizon, requiring further assessment of the effects on inter-
mediate risk factors for CVD to evaluate the public health consequences of a growing number of aging PLHIV.
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Data availability
The data that support the findings of this study are available from the Africa Health Research Institute Data 
Repository but restrictions apply to the availability of these data, which were used under license for the current 
study, and so are not publicly available.
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